Expression of p27kip1 is prognostic and independent of MYCN amplification in human neuroblastoma

International Journal of Cancer

Volumn 95, Issue 3, 2001, Pages 176-183

  Bergmann, Eckhard ^a   Wanzel, Michael ^b   Weber, Axel ^a   Shin, Inhee ^a   Christiansen, Holger ^a   Eilers, Martin ^b  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Cell proliferation; MYCN gene; Neuroblastoma; p27kip1

Indexed keywords

PROTEIN P27;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL CYCLE PROTEINS; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENE AMPLIFICATION; HUMANS; INFANT; INFANT, NEWBORN; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM STAGING; NEUROBLASTOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0035918537     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20010520)95:3<176::AID-IJC1030>3.0.CO;2-Z     Document Type: Article

References (56)

1. Morgan D. Principles of CDK regulation. Nature 1995;374:131-4.
2. 1-phase progression. Genes Dev 1999;13:1501-12.
3. Feru ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998;396:177-80.
4. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996;85:733-44.
5. Kiyokawa H, Kineman RD, Manova Todorova KO, Soares VC, Hoffman ES, Ono M, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 1996; 85:721-32.
6. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia(Kip1) retinal dysplasia, and pituitary tumors. Cell 1996; 85:707-20.
7. Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, et al. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A 1997;94:6380-5.
8. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al. Increased proteosome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-4.
9. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
10. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (Tla,b) invasive breast carcinomas. Cancer Res 1997;57:1259-63.
11. Maris JM. Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264.
12. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
13. Schwab M, Ellison J, Busch M, Rosenau W, Varmus HE, Bishop JM. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci USA 1984;81:4940-4.
14. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996;13:803-12.
15. Schwab M, Varmus HE, Bishop JM. Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture. Nature 1985;316:160-2.
16. Leone G, DeGregori J, Sears R, Jakoi L, Nevins JR. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 1997;387:422-6.
17. 1 cyclin/cdk complexes. EMBO J 1995;14:4814-26.
18. Alevizopoulos K, Vlach J, Hennecke S, Amati B. Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins. EMBO J 1997;16: 5322-33.
19. Rudolph B, Zwicker J, Saffrich R. Henglein B, Müller R, Ansorge W, et al. Activation of cyclin dependent kinases by Myc mediates transcriptional activation of cyclin A. but not apoptosis. EMBO J 1996; 15:3065-76.
20. Vlach J, Hennecke S. Alevizopoulos K, Conti D, Amati B. Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J 1996;15:6595-604.
21. Beier R, Bürgin A, Kiermaier A, Fero M, Karsunky H, Saffrich R, et al. Induction of cyclin E-cdk2 kinase activity, E2F-dependent transcription, and cell growth by Myc are genetically separable events. EMBO J 2000;21:5813-23.
22. Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, et al. Direct induction of cyclin D2 by Myc contributes to cell cycle induction and sequestration of p27. EMBO J 1999;18:5321-33.
23. O'Hagan RC, Ohh M, David G, de Alboran IM, Alt FW, Kaelin WG, Jr., et al. Myc-enhanced expression of cull promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes Dev 2000;14: 2185-91.
24. Perez-Roger I, Kim S-H, Griffiths B, Sewing A, Land H. Cyclins D1 and D2 mediate Myc-induced proliferation via sequestration of p27Kip1 and p21Cip1. EMBOJ 1999;18:5310-20.
25. Rosenwald IB, Lazaris-Karatzas A, Sonenberg N, Schmidt EV. Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E. Mol Cell Biol 1993;13:7358-63.
26. Borriello A, Pietra VD, Criscuolo M, Oliva A, Tonini GP, Iolascon A, et al. p27Kip1 accumulation is associated with retinoic-induced neuroblastoma differentiation: evidence of a decreased proteasome-dependent degradation. Oncogene 2000;19:51-60.
27. Matsuo T, Thiele CJ, p27Kip1: a key mediator of retinoic acid induced growth arrest in the SMS-KCNR human neuroblastoma cell line. Oncogene 1998;16:3337-43.
28. Bartkova J, Lukas J, Strauss M, Bartek J. Cell cycle-related variation and tissue-restricted expression of human cyclin D1 protein. J Pathol 1994;172:237-45.
29. Kaatsch P, Haaf G, Michaelis J. Childhood malignancies in Germany - methods and results of a nationwide registry. Eur J Cancer 1995;31A:993-9.
30. Shimada H, Chatten J, Newton WA, Jr., Sachs N, Hamoudi AB, Chiba T. et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984;73:405-16.
31. Muller D, Bouchard C, Rudolph B, Steiner P, Stuckmann I, Saffrich R. et al. Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes. Oncogene 1997;15: 2561-76.
32. Pagano M, Tam SW, Theodoras AM, Beer Romero P, Del Sal G, Chau V. et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-5.
33. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 1997;11:1464-78.
34. Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 1997;6: 5334-44.
35. Kawasaki H, Mukai K, Yajima S, Tanaka R, Takayama J, Takasaki Y, et al. Prognostic value of proliferating cell nuclear antigen (PCNA) immunostaining in neuroblastoma. Med Pediatr Oncol 1995;4:300-4.
36. Keim DR, Hailat N, Kuick R, Reynolds CP, Brodeur GM, Seeer RC, et al. PCNA levels in neuroblastoma are increased in tumors with an amplified N-myc gene and in metastatic stage tumors. Clin Exp Metastasis 1993;11:83-90.
37. Rudolph P, Lappe T, Hero B, Berthold F, Parwaresch R, Harms D, et al. Prognostic significance of the proliferative activity in neuroblastoma. Am J Pathol 1997;150:133-45.
38. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J 1992;11: 961-71.
39. Bastians H, Townsley FM, Ruderman JV. The cyclin-dependent kinase inhibitor p27(Kip1) induces N-terminal proleolytic cleavage of cyclin A. Proc Natl Acad Sci USA 1998;95:15374-81.
40. Orend G, Hunter T, Ruoslahti E. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells. Oncogene 1998;16:2575-83.
41. Singh SP, Lipman J, Goldman H, Ellis FH, Jr., Aizenman L, Cangi MG, et al. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998;58:1730-5.
42. Hawkins MM, Kingston JE, Kinnier Wilson LM. Late deaths after treatment for childhood cancer. Arch Dis Child 1990;65:1356-63.
43. Robertson CM, Hawkins MM, Kingston JE. Late deaths and survival after childhood cancer: implications for cure. BMJ 1994;309:162-6.
44. Scars R, Ohtani K, Nevins JR. Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals. Mol Cell Biol 1997;17:5227-35.
45. 1 arrest pathway. Mol Cell Biol 1999;19:5913-22.
46. Weinberg RA, Telomeres. Bumps on the road to immortality. Nature 1998;396:23-4.
47. Greenberg RA, O'Hagan RC, Deng H, Xiao Q, Hann SR, Adams RR, et al. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 1999;18:1219-26.
48. Wang J, Xie LY, Allan S, Beach D, Hannon GJ. Myc activates telomerase. Genes Dev 1998;12:1769-74.
49. Wu KJ, Grundori C. Amacker M, Simon-Vermot N, Polack A, Lingner J, et al. Direct activation of TERT transcription by c-MYC. Nat Genet 1999;21:220-4.
50. Hiyama E, Hiyama K, Yokoyama T, Fukuba I, Yamaoka H, Shay JW, et al. Rapid detection of MYCN gene amplification and telomerase expression in neuroblastoma. Clin Cancer Res 1999;5:601-9.
51. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995;1:249-55.
52. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993;328:847-54.
53. Nakagawara A, Brodeur GM. Role of neurotrophins and their receptors in human neuroblastomas: a primary culture study. Eur J Cancer 1997;33:2050-3.
54. Chen J. Chattopadhyay B, Venkatakrishnan G, Ross AH. Nerve growth factor-induced differentiation of human neuroblastoma and neuroepithelioma cell lines. Cell Growth Differ 1990;1:79-85.
55. Maruyama K, Schiavi SC, Huse W, Johnson GL, Ruley HE. myc and E1A oncogenes alter the responses of PC12 cells to nerve growth factor and block differentiation. Oncogene 1987;1:361-7.
56. Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 1992;52:1364-8.